Despite the advancement of the diagnostic and treatment tools, the median 5-years survival for the disease varies (58-85%), with regard to the fact that most survivors are treated when diagnosed in the lower stage of the disease. The suspected risk factors for breast cancer include the positive family history of the disease, long-term estrogen exposure, first child birth after 35 years of age, white race, Asian or Hispanic race, obesity, genetic predisposition, and the age above 50 years. The latter is the most important risk factor orchestrating the cellular breast changes towards the dysplasia and malignancy. Currently, suspicious patients for breast cancer are screened by radiologic studies, including ultrasonography (US), mammography; pathology; BI-RADS; breast cancer; screening

Key words: Ultrasonography; mammography; breast cancer; BI-RADS; pathology; screening

Received: 23 June 2020
Revised: 01 August 2020
Accepted: 06 August 2020

Introduction
The breast cancer is the first cause of cancer-related death among females between 20 and 44 years. The incidence of new cases reached 7778 patients per year, and the specific age-related incidence reported 22.6 (95% CI 22.1-23.1) patients per every 100,000 females, with an age-standardized rate (ASR) of 27.4 (95% CI 22.5-35.9) in Iran.
mammography, and magnetic resonance imaging (MRI). However, the diagnosis should be confirmed by the pathology reports. The ultrasonography is a non-invasive screening procedure specifically for finding the lesions in the dense breasts. The sensitivity of the US as an operator-dependent tool is about 70-90% and specificity has been reported to be widely different. On the other hand, the sensitivity and specificity of mammography vary between 55-90% and 70-97%, respectively. Concurrent use of US and mammography can decrease the false-negative reports to about 0.06% although in larger or more advanced tumors, the accuracy of either the US or mammography for estimating the size of the tumor has been decreased. Because of very low false-negative results of the screening studies, today, the concurrent use of the US and the mammography has been accepted as a common approach for breast tumor evaluation, preoperatively. Some studies have revealed that mammography had more advantageous results than did the US for demonstrating the tumor characteristics; however, some others have contradicted this result. Considering the review articles, the breast characteristics of every patient could be a guide to select which single available radiologic approach would be better for the patient. For example, in breasts with lower fat mass, the US and the MRI are more accurate than the mammography. This study was conducted to evaluate US and mammography findings for the breast lesions with regard to the pathologic reports.

Methods

The data was obtained from the registered medical files of the females pursuing breast examination either for the screening or diagnostic purposes (following symptoms), from May 2017 to October 2018. Ethical approval was obtained from the research ethics committee of the university (P/39/6/1/3264). The participants were randomly selected from the total of 630 registered medical files. Overall, from 252 files met inclusion criteria, and 126 samples were included through systematic random sampling. All the participants signed a written consent form for anonymous use of their data for research purposes. Exclusion criteria included the presence of inflammatory disease either locally in the breast (granulomatous mastitis) or systemic (like rheumatoid arthritis), positive history of breast, axillary or chest wall biopsy, previous thoracic surgery or irradiation, previous chemotherapy through the past 12 months of examination, presence of active skin and joint disease, ongoing pregnancy or consumption of oral contraceptives, tamoxifen or corticosteroids and need for axillary lymph node dissection. All patients were examined by a single general surgeon in a single public referral health care center. Females underwent breast examination, US and mammography study, and the breast mass biopsy was taken with core needle biopsy or open incisional or excisional approaches. The Breast Imaging-Reporting and Data System (BI-RADS) was considered for radiologic findings introduction. It is an accepted international scaling system to assess the breast mass characteristics and applied as a guide for the next step in clinical approach. The current study considered data of the US and the mammography reports with BI-RADS 0-4. The breast US had been performed by a single radiologist. The reports of both US and mammography were interpreted for all participants by the two attending physicians of the radiology department with over 12 years of experience. Finally, all reports are reviewed and corrected according to the revisions of an experienced radiologist who was an expert in breast imaging. After every patient underwent US and mammography, she was considered a candidate for the breast mass biopsy. Based on the guidelines for the management of breast cancer, BI-RADS 2-4 needs further pathology assessment while, in this study, biopsy was also taken from patients with BI-RADS 2 and 3. The reason for the latter was one of the following considerations:

1. Positive family history of breast cancer in either first or second degree relatives.
2. Positive family history of the breast cancer in a male relative.
3. Discordance between physical examination and radiologic report.
4. Patients who were considered to be unable to return for timely follow-up.
5. Patients who insisted to have a breast biopsy.

Breast biopsy was performed using one of the two following approaches by the surgeon: core needle biopsy (CNB) with the sterile 14 gauge biopsy needle (TSK ACECUT-Japan) under radiologic guide, or the surgical approach through incisional or excisional mass resection in the operating room. Specimens were sent to the reference hospital laboratory both in formalin and normal saline. The pathologic study as the definitive gold standard for making the diagnosis was performed by a single attending pathologist. The pathologic reports were classified as benign or malignant.

Demographic data in addition to US, mammography and the pathologic reports were used for analysis and interpretation. Frequency of categorical variables, central tendency statistics for continuous variables, sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of US and the mammography were calculated using SPSS version 21. Independent sample T test, Fisher exact test, Chi-square were used to examine the association of the variables. The Youden’s index (sensitivity+specificity-1) was applied for dichotomous diagnostic tests. Statistical analysis for agreement indexes including Kendall’s, Gamma and
Kappa were also run. To demonstrate the precise convergence of data, the ROC curve was customized. The significance level of $p$ was considered 0.05 or the lower. Also the findings were reported in line with the STROCSS criteria.\textsuperscript{12}

**Results**

The mean age ($\pm$SD) of 126 the participants was 55.2$\pm$13.9. Of all, 42(33.3\%) of the study sample had positive family history of breast cancer. Considering the pathology report as the gold standard for cancer diagnosis, eventually, 76(60.3\%) specimens were categorized as benign and the rest 50(39.7\%) showed evidence of malignancy. Breast ultrasonography and mammography findings based on the BI-RADS are shown in Table 1.

As demonstrated in Table 1, both US and mammography results demonstrated complete concordance with those of pathologic signs for the malignancy. Breast ultrasonography and mammography showed an opposite pattern of association. The sensitivity and specificity for BI-RADS 3 and 4 were 67.9(95\%-confidence interval 62.8-73.1) and 92.8(95\%-confidence interval 90.4-95.1)\% respectively. The Youden’s index for study findings.

**Table 1. The concordance of US and mammography results with pathology reports**

| BI-RADS | Ultrasonography | Permanent pathologic report | Mammography | P value |
|---------|----------------|-----------------------------|-------------|---------|
|         | Benign | Malignant | Total n (%; in row/ in column) | Benign | Malignant | Total |
| 0-1     | 0     | 0        | 0                           | 0     | 0        | 0     |
| 2       | 48(100/63.2) | 0 | 48(100/38.1) | 50(100/65.8) | 0 | 50(100/39.7) | 0.7 |
| 3       | 25(100/32.9) | 0 | 25(100/19.8) | 22(100/28.9) | 0 | 22(100/17.5) | 0.8 |
| 4       | 2(5.7/6.2) | 33(94.3/66.0) | 35(100/27.8) | 4(28.6/5.3) | 10(71.4/20.0) | 14(100/11.1) | <0.001 |
| 5       | 1(5.6/1.3) | 17(94.4/34.0) | 18(100/14.3) | 0(0) | 40(100/80.0) | 40(100/31.7) | <0.01 |
| Total   | 76(100/60.3) | 50(100/39.7) | 126(100/100) | 76(100/60.3) | 50(100/39.7) | 126(100/100) |

Table 2 shows lower sensitivity and NPV for higher BI-RADS. This is while specificity and PPV showed an opposite pattern of association. The overall sensitivity, specificity, PPV, and NPV for US (mammography) were 69.8 (91.9\%), 71.9 (76.6\%), 75.6 (80.8\%), and 81.3 (94.6\%) percent, respectively. The Youden’s index to detect breast lesions was 0.46 for US and 0.68 for mammography. Customizing ROC curve for mammography and pathology reports demonstrated that for BI-RADS 4, we had the highest overall sensitivity (94.3\%) and specificity (94.5\%) for screening malignancy. ROC curve for US and pathology showed the highest overall sensitivity (68-92\%) and specificity (73-96\%) for the BI-RADS 3 and 4. Considering the permanent pathology study for each patient, the convergence of the US and the mammography results is demonstrated in Table 3.

The colored cells in Table 3 show concordance between US and mammography results considering pathology reports as the gold standard, within each BI-RADS stratum. The overall concordance between radiology and pathology (shown as grey in Table 3) was observed in 42 subjects (33.3\%).

**Table 2. Diagnostic statistics for US and mammography for breast malignancy considering pathology as the gold standard findings**

| Radiologic modality | BI-RADS | Sensitivity | Specificity % (95\%-confidence interval) | PPV\textsuperscript{1} | NPV\textsuperscript{2} | Youde’s index | P for Youde’s index |
|---------------------|---------|-------------|------------------------------------------|------------------------|------------------------|---------------|---------------------|
| Ultrasonography     | 2       | 96.2(94.1-97.3) | 20.5(14.3-27.7) | 46.7(38.3-55.4) | 88.2(83.8-93.4) | 0.16 | <0.01 |
|                     | 3       | 92.4(89.1-95.7) | 72.6(65.7-80.5) | 71.0(66.6-76.4) | 92.9(89.1-95.3) | 0.65 | 0.32 |
|                     | 4       | 67.9(59.3-73.8) | 95.8(93.2-98.6) | 92.3(88.2-96.4) | 80.4(74.6-87.8) | 0.63 | 0.78 |
|                     | 5       | 22.6(11.8-34.6) | 98.6(96.9-99.4) | 92.3(87.4-97.3) | 63.7(55.3-72.6) | 0.40 | 0.51 |
|                     | 2-5     | 69.8(61.6-76.3) | 71.9(65.2-77.7) | 75.6(70.2-80.8) | 81.3(72.2-90.4) | 0.46 | 0.78 |
| Mammography         | 2       | 100          | 32.0(20.9-45.2) | 51.9(42.5-61.1) | 100          | 0.32 | 0.01 |
|                     | 3       | 98.0(96.8-99.2) | 80.0(73.5-88.4) | 78.8(73.4-81.9) | 98.3(96.5-99.1) | 0.78 | 0.32 |
|                     | 4       | 94.3(92.4-96.3) | 94.5(92.3-96.8) | 92.5(88.6-96.4) | 95.8(94.6-97.2) | 0.88 | 0.51 |
|                     | 5       | 75.4(68.8-80.1) | 100          | 84.8(81.3-87.6) | 84.8(81.3-87.6) | 0.75 | 0.01 |
|                     | 2-5     | 91.8(87.3-95.6) | 76.6(70.2-83.8) | 80.8(73.8-87.5) | 94.6(92.3-96.8) | 0.68 | 0.01 |

\textsuperscript{1}: Positive Predictive Value  \textsuperscript{2}: Negative Predictive Value
Table 3. The convergence of breast US with mammography in BI-RADS model based on pathology as the gold standard findings

| BI-RADS | Mammography n(%) | Total n(%) |
|---------|------------------|-----------|
|         | 1 | 2 | 3 | 4 | 5 |         |          |
| US      | 1 | 6(4.8) | 9(7.1) | 2(1.6) | 0 | 0 | Benign | 66(52.4) |
|         | 2 | 12(9.5) | 19(15.1) | 7(5.6) | 1(0.8) | 1(0.8) |         |          |
|         | 3 | 6(4.8) | 10(7.9) | 1(0.8) | 3(2.4) | 11(8.7) | 16(12.7) |          |
|         | 4 | 0 | 2(1.6) | 0 | 5(4.0) | 19(15.1) |         |          |
|         | 5 | 0 | 0 | 0 | 1(0.8) | 11(8.7) | 2(1.6) |          |

| Benign | Malignant | Pathology |
|--------|-----------|-----------|
| 42(33.3%) |          |          |

Furthermore, overall complete or relative compatibility (pink and grey cells in Table3: 66+42) was observed for 108(85.7%) of cases. Furthermore, mammography over-diagnosed 12.7% of the benign lesions as malignant while the US study underestimated 1.6% of malignant lesions as the benign one.

Discussion

This study examined diagnostic accuracy and concordance of US and mammography stratified by BI-RADS and considering pathology reports as the gold standard on 126 study participants, of which 60% proved to be benign and 40% malignant. Since 1960 when mammography was first implemented, early discovery of asymptomatic breast cancer has increased and conclusively mortality rate has dropped to 25% accompanied with a 90% increase in true-positive findings. Mammography is more accurate than physical examination to find masses and detect micro-calcification. Fortunately, recent results have shown that three-dimensional mammography could be even more powerful to diagnose breast malignancies and is also associated with a lower false-positive reports in comparison with the traditional type.1 Although there are numerous studies in the medical literature on sensitivity and specificity of breast US and mammography based on definite pathology as the gold standard, the concordance between these two radiologic modalities has been less frequently investigated. This paper revealed a higher sensitivity for mammography (75.4-100%) in comparison with US (22.6-96.2%), the fact that has been confirmed by previous studies (33-56% for the US versus 36-88% for mammography).13,14 Moreover, in each BI-RADS category, mammography was more sensitive than US. Additionally, sensitivity of both the US and mammography was lower for higher BI-RADS13,14 while an opposite result was found for specificity which was in line with some other studies.13,17 However, some studies have disputed this finding claiming that US was more sensitive than mammography.16-18 The differences in conclusions might be attributable to patients’ characteristics in different studies (such as sample size, menopausal status of patients, genetics, and some breast characteristics, for example large breasts or breasts with higher fat composition) and/or other factors (such as instruments and equipment, and also operators’ technical skills). MRI has also been introduced as a screening instrument and its concordance with US and mammography has been studied.17-19

The current study showed a relative concordance between US and mammography based on pathologic reports. It also revealed that findings from mammography had both a higher overall correlation with pathology and a lower underestimation of the disease in comparison to US. The US results were accompanied with over 12% overestimation of the benign lesions as malignant. However, more data needs to be carried out but this study argues that implementation of both US and mammography in breast lesions with the BI-RADS≥4 would not be necessary, when one of them is performed. Moreover, in BI-RADS 2 and 3, complete concordance with pathology was observed and no further invasive assessments were required.

This study was conducted on available patients records in a single medical center with a limited number of participants. Lack of simultaneous application of US and mammography was another limitation. Moreover, symptomatic and asymptomatic patients seeking breast screening were pooled and thus not analyzed as separate groups.

In conclusion, both ultrasonography and
mammography were shown to be sensitive and specific imaging modalities for screening breast lesions, particularly for malignancy. The relative concordance rate between these two screening modalities was acceptable. However, the overall performance of mammography was better than that of US in all breast lesions, especially for the malignant ones. US exhibited some over-diagnosis of benign lesions as malignant ones. Invasive biopsy taken in suspected cases with the BI-RADS 2 and 3 is not recommended, based on the results of the current study.

Conflicts of Interests
All authors admitted to having no financial or professional benefits to in this study.

References
1. Brunicardi CH, Anderesen DK, Billiar TR, Dunn DL and et al. Schwartz’s principles of surgery 10th edition. Mc Graw Hill: Newyork. 2019;11(17):541-612.
2. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519-527.
3. Reeder JG and Vogel VG. Breast cancer prevention. Cancer treatment and research.2008; 141:149-64.
4. Lee IM, Shiroma EJ, Lobelo F, Puska P and et al. Effect of physical inactivity on major non-communicable disease worldwide: an analysis of burden of disease and life expectancy. The Lancet. 2012; 380(9838):219-29.
5. Devolli-Disha E, Manxhuka-Kerliu S, Ymeri H, Kutlllovci A. Comparative accuracy of mammography and ultrasound in women with breast symptoms according to age and breast density. Bosn J basic Med Sci.2009; 9:131-6.

5. Devolli-Disha E, Manxhuka-Kerliu S, Ymeri H, Kutlllovci A. Comparative accuracy of mammography and ultrasound in women with breast symptoms according to age and breast density. Bosn J basic Med Sci.2009; 9:131-6.

6. Flobbe K, Bosch AM, Kesseles AG, Beets GL and et al. The additional diagnosis value of ultrasonography in the diagnosis of breast cancer; Arch Intern Med.2003;163(10):1194-9.
7. Geller BM, Vacek PM, Skelly J and Harvey SC. The use of additional imaging increased specificity and decreased sensitivity in screening mammography. J Clin Epidemiol.2005; 58(9):942-50.
8. Kriege M, Brekelmans CT, Obdeijn IM, Boetes C and et al. Factors affecting sensitivity and specificity of screening mammography and MRI on women with inherited risk for breast cancer. Breast cancer Res Treat.2006;100:109-19.
9. Kim MJ, Kim EK, Kwak JY, Park BW and et al. Sonography surveillance for detection of contralateral metachronous breast cancer in an Asian population. AJR AM J Roentgenol.2009; 192(1):221-8.
10. Siqueira FM, Rezende CA and Barra A. Correlation between clinical examination, mammography and ultrasonography with histopathological exam in determination of tumor size in breast cancer. Rev Bras Ginecol Obstet.2008;30:107-12.
11. Shoma A, Moutamed A, Ameen M and Abdelwahab A. Ultrasound for accurate measurement for invasive breast cancer tumor size. Breast J.2006;12:252-6.
12. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C and Mathew G, for the STROCSS Group. The STROCSS 2019 Guideline: Strengthening the Reporting of Cohort Studies in Surgery. International Journal of Surgery.2019;72:156-65.
13. Ko ES, Lee HA, Kim WC, Noh MS and et al. Triple negative breast cancer: correlation between imaging and pathological findings. European Radiology.2010;20(5):1111-7.
14. Boyd NF, Guo H, Martin LJ, Sun L and et al. Mammography density and the risk and detection of breast cancer. NEJM.2007; 356(3):227-36.
15. Haghighatkhah HR. Evaluation of concordance of mammography and ultrasonography reports with histopathology reports in benign and malignant breast disease. IJBD.2009; 2(2):27-32.
16. Berg WA, Zhang Z, Lehrer D, Jong RA and et al. detection of breast cancer with addition annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA.2012;307(13) :1394-404.
17. Yeh E, Slantez P, Kopans DB, Rafferty E and et al. Prospective comparison of mammography, sonography and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. American J of Roentgenology.2005; 184(3): 868-77.
18. Group MS. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multi center cohort study (MARIBS). The Lancet.2005;365(9473):1769-78.
19. Lord S, Lie W, Craft P, Cawson J and et al. A systematic review of the effectiveness of magnetic resonance imaging as an addition to mammography and ultrasound in screening of women at high risk of breast cancer. European J of cancer.2007; 43(13):1905-17.